Deal supported by Xplico
Bavarian Nordic Enters Licensing and Collaboration Agreement with Janssen for MVA-BN® in the Development of a Therapeutic HPV Vaccine.
Deal supported by Xplico
LEO Pharma to acquire global dermatology portfolio from Astellas.
Deal supported by Xplico
ObsEva and Kissei Pharmaceutical Announce Global Agreement to Develop and Commercialize KLH-2109 for the Treatment of Endometriosis.
Deal supported by Xplico
Sanofi and Lexicon Pharmaceuticals to Collaborate on Sotagliflozin, an Investigational New Oral Medicine for People with Diabetes.
Deal supported by Xplico
Nuevolution Announces Drug Discovery Collaboration with Johnson & Johnson Innovation.
Deal supported by Xplico
PharmaMar announces license agreement with Specialised Therapeutics Australia Pty for
APLIDIN® (plitidepsin) in oncology.
Deal supported by Xplico
Inovio Pharmaceuticals enters into Strategic Cancer Vaccine Collaboration and License Agreement with MedImmune
Deal supported by Xplico
PharmaMar announces license agreement with TTY Biopharm for APLIDIN® (plitidepsin) in hematological cancers
Deal supported by Xplico
LEO Pharma Enters Supply and Distribution Agreement with NeoPharm on Non-Prescription Skin Care Solutions
Xplico launchs Xplico Consolidation – a company valuation tool to support funding & M&A activities
We are pleased to announce that we have released the first version of the Xplico Evaluator consolidation module Xplico Consolidation. The consolidation module enables you in a very easy way to get the company valuation […]